The goal of this SBIR Phase I project is the development of a new drug discovery platform for screening new inhibitors of viral polymerases and for studying mechanisms of action of the prospective pharmaceutical compounds. The main innovation in this project is the proposed concept of a multi-enzyme assay, which is able to measure efficiency and identify the mechanism of action of a viral polymerase inhibitor in a single experiment using a small reaction volume in realtime detection mode using widely available commercial instruments (luminometers). The proposed platform is superior over the existing methods in that it substantially reduces the cost of reagents, reduces the assay time from days to minutes and is adaptable to high-throughput format for application in large and small scale drug discovery projects. The proposed SBIR project is in response to the NIH call for new approaches aimed at reducing costs and increasing speed of preclinical drug development.
Public Health Relevance: Antiviral therapy represents an important frontier for development of potential lifesaving products. Worldwide, millions of people suffer from viral infections each year. Approximately 360 million people worldwide suffer from hepatitis B virus, the major cause of liver cancer. Worldwide more than 170 million people are infected with hepatitis C, the leading cause of acute liver inflammation and liver cancer. Around the world more than 42 million people are infected with lifethreatening human immunodeficiency virus (HIV), including more than 3 million children. To address the growing medical needs, there is a steady increase in the number of antiviral compounds in development. The proposed SBIR project will create a knowledge base and establish a new technology, which reduces the cost and time of developing pharmaceutical antiviral products with a large health impact in the USA and around the world.
Thesaurus Terms: 0-11 Years Old; 21+ Years Old; Aids Virus; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Acute; Address; Adult; Antiviral Agents; Antiviral Drugs; Antiviral Therapy; Antivirals; Area; Assay; Bioassay; Biologic Assays; Biological Assay; Businesses; Cmv; Child; Child Youth; Children (0-21); Collaborations; Cytomegalovirus; Dna; Dna, Viral; Dna-Dependent Rna Polymerases; Dna-Directed Rna Polymerase; Deoxyribonucleic Acid; Detection; Development; Diagnosis; Disease; Disorder; Drug Compounding; Drug Development, Preclinical; Drug Preparation; Drug Testing/Development, Preclinical; Drugs; Ec 2.7.7.48; Ec 2.7.7.6; Enzymes; Event; Fees; Gene Products, Rna; Goals; Grippe; Hbv; Hcmv; Hcv; Hcv Infection; Hiv; Hiv-1; Hiv-I; Hiv1; Hpv; Htlv-Iii; Health; Hepatic Cancer; Hepatitis B; Hepatitis B Infection; Hepatitis B Virus; Hepatitis C; Hepatitis C Virus; Hepatitis C Virus Infection; Hepatitis Virus, Homologous Serum; Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted; Hepatitus C; Herpes Genitalis; Herpes Simplex, Genital; Housing; Human Immunodeficiency Viruses; Human Papillomavirus; Human T-Cell Leukemia Virus Type Iii; Human T-Cell Lymphotropic Virus Type Iii; Human T-Lymphotropic Virus Type Iii; Human Immunodeficiency Virus 1; Human, Adult; Human, Child; Inflm; Immunodeficiency Virus Type 1, Human; Infant; Infection; Infectious Human Wart Virus; Inflammation; Influenza; Lav-Htlv-Iii; Letters; Libraries; Life; Liver; Lymphadenopathy-Associated Virus; Malignant Neoplasm Of Liver; Measures; Medical; Medication; Methods; Mission; Molecular; Nanbh; Nih; National Institutes Of Health; National Institutes Of Health (U.S.); Nucleoside-Triphosphate[{..}]rna Nucleotidyltransferase (Dna-Directed); Nucleoside-Triphosphate[{..}]rna Nucleotidyltransferase (Rna-Directed); Nucleosides; Pt-Nanbh; Papilloma Virus, Human; Papillomavirus, Human; Parenterally-Transmitted Non-A, Non-B Hepatitis; Performance; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Phase; Polymerase; Preclinical Drug Development; Production; Programs (Pt); Programs [publication Type]; Protocol; Protocols Documentation; Rna; Rna Polymerases; Rna Replicase; Rna, Non-Polyadenylated; Rna, Viral; Rna-Dependent Rna Polymerase; Rna-Directed Rna Polymerase; Reaction; Reagent; Recombinants; Research; Ribonucleic Acid; Sbir; Sbirs (R43/44); Salivary Gland Viruses; Screening Procedure; Services; Small Business Innovation Research; Small Business Innovation Research Grant; Speed; Speed (Motion); Technology; Tennessee; Time; United States; United States National Institutes Of Health; Universities; Vaccine Research; Viral; Viral Diseases; Viral Genome; Viral Hepatitis B; Virus; Virus Diseases; Virus Inhibitors; Virus-Genital Herpes; Virus-Hiv; Viruses, General; Work; Adult Human (21+); Base; Body System, Hepatic; Children; Clinical Significance; Clinically Significant; Commercialization; Congenital Cytomegalovirus; Congenital Cytomegalovirus Infection; Cost; Cytomegalovirus Group; Disease/Disorder; Drug Discovery; Drug/Agent; Experiment; Experimental Research; Experimental Study; Flu Infection; Frontier; Genital Herpes; Hepatitis Non A Non B; Hepatitis Nona Nonb; Herpes Genitalia; Human T Cell Leukemia Virus Iii; Human T Lymphotropic Virus Iii; Human Cytomegalovirus; Influenza Infection; Inhibitor; Inhibitor/Antagonist; Innovate; Innovation; Innovative; Instrument; Interest; Knowledge Base; Liver Cancer; Malignant Liver Tumor; Meetings; New Approaches; New Technology; Non A Non B Hepatitis; Non A, Non B Hepatitis; Non-A Non-B Hepatitis; Non-A, Non-B Hepatitis; Novel Approaches; Novel Strategies; Novel Strategy; Nucleoside Inhibitor; Organ System, Hepatic; Programs; Prospective; Public Health Relevance; Research Study; Response; Screening; Screenings; Serum Hepatitis; Treatment Of Viral Infectious Disease; Venereal Herpes; Viral Dna; Viral Rna; Viral Infection; Viral Inhibitor; Virus Dna; Virus Rna; Virus Infection; Wart Virus; Youngster
